BFM
CARM

Boothbay Fund Management’s Carisma Therapeutics CARM Stock Holding History

Boothbay Fund Management’s Portfolio CARM Stock Details CARM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-2,274
Closed -$37K – 2265
2022
Q2 		$37K Buy
+2,274
New +$26K ﹤0.01% 2109
2021
Q1 		– Sell
-1,000
Closed -$27K – 1557
2020
Q4 		$27K Buy
+1,000
New +$25.4K ﹤0.01% 1198

Other funds holding CARM

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Group One Trading
Group One Trading Chicago, Illinois $52.2B AUM 104.56% 1-Year Est. Return
SWP
Stratos Wealth Partners Beachwood, Ohio $8.8B AUM 21.82% 1-Year Est. Return

Boothbay Fund Management's CARM Position: Q3 2022 in Review

Boothbay Fund Management sold out of Carisma Therapeutics (CARM) in Q3 2022, closing a stake of 2,274 shares — an estimated $37K sold.

Boothbay Fund Management first reported a position in CARM in Q4 2020 and held it in 2 quarters. The position peaked at $37K in Q2 2022. 68 funds tracked by Wall St. Rank hold CARM as of Q3 2022.

  • Boothbay Fund Management reported no remaining Carisma Therapeutics position as of Q3 2022 after selling out during the quarter.
  • Boothbay Fund Management sold 2,274 Carisma Therapeutics shares in Q3 2022, an estimated $37K.
  • Boothbay Fund Management first reported a position in Carisma Therapeutics in Q4 2020 and held it in 2 quarters.
  • Boothbay Fund Management's Carisma Therapeutics position peaked at $37K in Q2 2022.
  • 68 funds tracked by Wall St. Rank held Carisma Therapeutics as of Q3 2022.

Based on Boothbay Fund Management's 13F filing for Q3 2022, filed 14 Nov 2022.